TSXV - Delayed Quote CAD
Cytophage Technologies Ltd. (CYTO.V)
At close: October 18 at 3:59 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Steven Theriault B.Sc., M.Sc., Ph.D. | CEO, Chief Science Officer & Director | 350k | -- | -- |
| Mr. Julius John Kalcevich M.B.A. | Chief Financial Officer | 225k | -- | 1975 |
| Ms. Heather Medwick B.A. | Chief Operating Officer | 200k | -- | -- |
| Mr. Michael Graham M.B.A. | Chief Commercialization Officer | 225k | -- | 1977 |
Cytophage Technologies Ltd.
26 Henlow Bay
Winnipeg, MB R3Y1G4
Canada
- Sector:?
- Healthcare
- Industry:? Biotechnology
Description
Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Winnipeg, Canada.
Corporate Governance
Cytophage Technologies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available